Your browser doesn't support javascript.
loading
Comparison between an immunochemical fecal occult blood test and a Guaiac based fecal occult blood test in detection of adenomas and colorectal cancer
Kupper, Bruna Elisa Catin; Aguiar Júnior, Samuel; Nakagawa, Wilson Toshihiko; Takahashi, Renata Mayumi; Batista, Ranyell Matheus Spencer Sobreira; Bezerra, Tiago Santoro; Stevanato Filho, Paulo Roberto; Chulam, Thiago Celestino; Lopes, Ademar.
  • Kupper, Bruna Elisa Catin; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Aguiar Júnior, Samuel; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Nakagawa, Wilson Toshihiko; A.C.Camargo Cancer Center. Colorectal Cancer Deparment. São Paulo. BR
  • Takahashi, Renata Mayumi; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Batista, Ranyell Matheus Spencer Sobreira; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Bezerra, Tiago Santoro; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Stevanato Filho, Paulo Roberto; A.C.Camargo Cancer Center. Colorectal Cancer Departament. São Paulo. BR
  • Chulam, Thiago Celestino; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
  • Lopes, Ademar; A.C.Camargo Cancer Center. Colorectal Cancer Department. São Paulo. BR
Appl. cancer res ; 38: 1-6, jan. 30, 2018. tab.
Article in English | LILACS, Inca | ID: biblio-910465
ABSTRACT

Background:

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Brazil does not have an official well established program for screening colorectal cancer. The aim of this study was to compare Guaiac Based Fecal Occult Blood Test (G-FOBT) to a kind of an Immunochemical Fecal Occult Blood Test (I-FOBT), in search of cancer or advanced adenoma.

Methods:

Prospective and cross-sectional study. Asymptomatic and average-risk individuals (n = 1500) aged from 50 to 75 years old were invited to participate in the study. The primary endpoint was positivity rate and the secondary endpoints were adherence rate and significant endoscopic findings. All participants received both tests with follow-up colonoscopy if either test was positive.

Results:

Adherence rate of G- FOBT was 756/1500 (50.4%) while for I- FOBT it was 960/1500(64%). The positivity ratio in the I- FOBT was 94/960 (9.8%) and in the G-FOBT was 20/771 (2.6%). The Positive Predict Value (PPV) for the I- FOBT counted 16/77 (21.0%) while for the G- FOBT it was 6/18 (33.0%), considering significant lesions. Regarding the colorectal cancer findings, the detection in the colonoscopy guided from the positivity of fecal occult blood tests was 5/77 (6.5%) in I- FOBT and 2/18 (11.1%) on the G- FOBT.

Conclusions:

The positivity, the adherence rate and the capacity to detect significant lesions were higher in I-FOBT. Considering the findings of the study we could conclude that I-FOBT was superior to G- FOBT. Trial registration This study was reviewed and approved by the Institutional Review Board of A.C.Camargo Cancer Center, São Paulo, Brazil, number 1877/14
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Colorectal Neoplasms / Adenoma / Mass Screening / Early Detection of Cancer / Occult Blood Type of study: Diagnostic study / Observational study / Prognostic study / Risk factors / Screening study Limits: Female / Humans / Male Language: English Journal: Appl. cancer res Journal subject: Neoplasms Year: 2018 Type: Article Affiliation country: Brazil Institution/Affiliation country: A.C.Camargo Cancer Center/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Colorectal Neoplasms / Adenoma / Mass Screening / Early Detection of Cancer / Occult Blood Type of study: Diagnostic study / Observational study / Prognostic study / Risk factors / Screening study Limits: Female / Humans / Male Language: English Journal: Appl. cancer res Journal subject: Neoplasms Year: 2018 Type: Article Affiliation country: Brazil Institution/Affiliation country: A.C.Camargo Cancer Center/BR